Vallon Pharmaceuticals, Inc. (VLON)
| Market Cap | 4.20M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -8.76M |
| Shares Out | 10.51M |
| EPS (ttm) | -1.36 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 243,984 |
| Open | 0.394 |
| Previous Close | 0.395 |
| Day's Range | 0.380 - 0.400 |
| 52-Week Range | 0.340 - 10.360 |
| Beta | n/a |
| Analysts | Buy |
| Price Target | 12.24 (+2,962.3%) |
| Earnings Date | Aug 9, 2022 |
About VLON
Vallon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel medications for central nervous system disorders with a focus on abuse-deterrent medications. Its lead investigational product candidate is ADAIR, an abuse-deterrent oral formulation of immediate-release dextroamphetamine for the treatment of attention-deficit/hyperactivity disorder (ADHD) and narcolepsy. The company is also developing ADMIR, an abuse deterrent formulation of methylphenidate for the treatment of ADHD. Vallon Phar... [Read more...]
Financial Performance
Financial StatementsAnalyst Forecast
According to 7 analysts, the average rating for VLON stock is "Buy." The 12-month stock price forecast is 12.24, which is an increase of 2,962.30% from the latest price.
News
Vallon Pharmaceuticals Announces $3.9 Million Registered Direct Offering
PHILADELPHIA, PA, May 13, 2022 (GLOBE NEWSWIRE) -- Vallon Pharmaceuticals, Inc. (NASDAQ: VLON), (“Vallon” or the “Company”), a clinical-stage biopharmaceutical company primarily focused on the developme...
Vallon Pharmaceuticals Announces Issuance of Japanese Patent Covering Composition of Matter and Methods of Manufactur...
PHILADELPHIA, PA, May 11, 2022 (GLOBE NEWSWIRE) -- Vallon Pharmaceuticals, Inc. (NASDAQ: VLON), (“Vallon” or the “Company”), a clinical-stage biopharmaceutical company primarily focused on the developme...
Vallon Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides Corporate Update
PHILADELPHIA, PA, May 09, 2022 (GLOBE NEWSWIRE) -- Vallon Pharmaceuticals, Inc. (NASDAQ: VLON), (“Vallon” or the “Company”), a clinical-stage biopharmaceutical company primarily focused on the developme...
Top Penny Stocks Today: Why VLON, MITQ, HCDI, BKEP Stocks Are Soaring Friday
It's time for another breakdown of the top penny stocks that investors need to keep an eye on with the biggest movers for Friday! The post Top Penny Stocks Today: Why VLON, MITQ, HCDI, BKEP Stocks Are S...
Why Is Vallon Pharmaceuticals (VLON) Stock Up 90%+ Today?
Vallon Pharmaceuticals (VLON) stock is rocketing higher on Friday after the company announced it's considering strategic alternatives. The post Why Is Vallon Pharmaceuticals (VLON) Stock Up 90%+ Today?
Vallon Pharmaceuticals stock is the biggest gainer and most active after exploring possible sale
Shares of Vallon Pharmaceuticals Inc. VLON, +96.81% skyrocketed 89.0% on massive volume in morning trading Friday after the biopharmaceutical company said it is exploring strategic alternatives, includi...
Vallon Pharmaceuticals Announces Review of Strategic Alternatives
Philadelphia, PA, April 22, 2022 (GLOBE NEWSWIRE) -- Vallon Pharmaceuticals, Inc. (NASDAQ: VLON), (“Vallon” or the “Company”), a clinical-stage biopharmaceutical company primarily focused on the develop...
Vallon (VLON) Plummets as ADAIR Study Misses Primary Goal
Vallon Pharmaceuticals (VLON) down as SEAL study evaluating lead investigational product candidate, ADAIR, fails to meet its primary endpoint.
Vallon Pharmaceuticals Announces Appointment of Meenu Karson to Board of Directors
Global b iopharmaceutical industry senior executive with over 15 years of operational leadership with transactional and capital markets experience spanning both private and public large pharma and small...
Vallon Pharmaceuticals Announces Issuance of U.S. Patent Covering ADAIR for the Treatment of Cognitive Impairment Ass...
- Company in ongoing disc ussions with a major academic research center for design and execution of proof-of-concept study evaluating ADAIR for the treatment of cognitive impairment associated with COVI...
Vallon Pharmaceuticals Reports Fiscal Year 2021 Financial Results and Provides Business Update
- T opline data for p ivotal abuse study of the C ompany's lead investigational program ADAIR expected this quarter
Vallon Pharmaceuticals to Present at the Virtual Investor 2022 Top Picks Conference
– Liv e video webcast presentation on Tuesday, January 25 th at 9:00 AM ET
Vallon Pharmaceuticals Presents New Data from Adult Stimulant Abuse Pattern Survey at the APSARD 2022 Annual Conference
- Survey r esults reinforce existing literature that immediate-release ( IR ) amphetamine s, such as Adderall ® , are the most commonly abused preparation of prescription stimulants
Vallon Pharmaceuticals to Present at the H.C. Wainwright BioConnect Conference
PHILADELPHIA, PA, Jan. 04, 2022 (GLOBE NEWSWIRE) -- Vallon Pharmaceuticals, Inc. (NASDAQ: VLON), (“Vallon” or the “Company”), a clinical-stage biopharmaceutical company primarily focused on the developm...
Vallon Pharmaceuticals Announces Achievement of Last Patient Last Visit in Pivotal SEAL Study for Lead Program, ADAIR
- Topline results f ro m p ivotal SEAL study expected in Q1 2022
5 Short Squeeze Candidates To Watch: Petros Pharmaceuticals, iSpecimen Top The List Again
Potential short squeeze plays have gained steam in 2021 with new retail traders looking for the next huge movie. GameStop Corp (NYSE:GME) and AMC Entertainment Holdings (NYSE:AMC) are two high-profile e...
5 Short Squeeze Candidates To Watch: Petros Pharma Tops List With 254% Cost To Borrow, One Of Highest Figures On Record
Potential short squeeze plays have gained steam in 2021 with new retail traders looking for the next huge move. GameStop Corp (NYSE: GME) and AMC Entertainment Holdings (NYSE: AMC) are two high-profile ...
Vallon Pharmaceuticals Reports Third Quarter 2021 Financial Results and Provides Corporate Update
- Ongoing pivotal intranasal abuse study of l ead program, ADAIR, advancing toward completion of patient enrollment and treatment in Q1 2022
Vallon Pharmaceuticals to Present at the Virtual Investor Roundtable Event
- Live moderated video webcast discussion among members of management and ADHD and a buse e xpert, Stephen V. Faraone, Ph.D., on T hurs day, November 18 th at 3 :00 P M ET
Vallon Pharmaceuticals to Present at the H.C. Wainwright 7th Annual Israel Virtual Conference
- Live video webcast presentation on Monday, November 15 th at 8:30 am ET
Vallon Pharmaceuticals Presents Data from Adult Stimulant Abuse Pattern Survey at the American Academy of Child and A...
- Results suggest that developing stimulant formulations with abuse deterrent properties by non-oral routes may potentially reduce negative consequences of misuse, abuse, and diversion of stimulant medi...
Vallon Pharmaceuticals Provides Update on Recent Pipeline and Corporate Advancements
- L ead program, ADAIR , advancing toward completion of patient enrollment and treatment in ongoing SEAL study
Vallon Pharmaceuticals Announces Formation of Scientific Advisory Board
- Inaugural a ppointments include globally renowned leaders and experts on attention-deficit/hyperactivity disorder (ADHD) and stimulant abuse
Vallon Pharmaceuticals to Present at the Q3 Virtual Investor Summit
Live video webcast with David Baker, President and CEO of Vallon , on Wednesday , August 18 th 12 : 30 PM ET
Vallon Pharmaceuticals Reports Second Quarter 2021 Financial Results and Provides Corporate Update
- Company continues to drive enrollment in pivotal intranasal abuse study evaluating ADAIR toward completion before year-end 2021